Simulations Plus Osake

Simulations Plus EBITDA

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Simulations Plus (SLP) 7.8.2026 päivämäärällä on −70,73 M USD. Edellisenä vuonna EBITDA (Tulos ennen korkoja, veroja ja poistoja) oli 6,13 M USD — muutos −1 253,63 % (matalampi).

EBITDA

−70,73 MUSD

YoY

−1 253,63%

Viimeksi päivitetty:

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Simulations Plus on 2026 −70,73 M USD. EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Simulations Plus oli 2025 6,13 M USD. Se laskee −1 253,63% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Simulations Plus Osakeanalyysi

Mitä Simulations Plus tekee? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Simulations Plus osakkeesta

Yhtiön Simulations Plus EBITDA (Tulos ennen korkoja, veroja ja poistoja) on −70,73 M USD vuonna 2026.

EBITDA (Tulos ennen korkoja, veroja ja poistoja) yhtiöstä Simulations Plus muuttui arvosta 6,13 M USD arvoon −70,73 M USD, mikä edustaa −1 253,63 % muutosta. Arvo on matalampi kuin edellisenä vuonna.

Eurpoolissa voit löytää EBITDA (Tulos ennen korkoja, veroja ja poistoja) Simulations Plus:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

EBITDA mittaa operatiivista suorituskykyä ennen rahoitusrakenteen, veroympäristön ja muiden kuin käteispoisto-osuuksien vaikutusta.

EBITDA = EBIT + Poistot

EBITDA (Tulos ennen korkoja, veroja ja poistoja):n USD on sijoittajille tärkeä tekijä. Muutokset tässä tunnusluvussa voivat signaloida parantuvia tai heikentyneitä perustekijöitä, mikä vaikuttaa suoraan osakekurssiin. Eulerpoolissa voit seurata EBITDA (Tulos ennen korkoja, veroja ja poistoja):n Simulations Plus historiallisesti ja reaaliajassa.

Access this data via the Eulerpool API

Tuloslaskelma — Simulations Plus

Kaikki tunnusluvut — Simulations Plus